In the last trading session, 5.39 million shares of the Organon & Co (NYSE:OGN) were traded, and its beta was 0.57. Most recently the company’s share price was $8.69, and it changed around $0.0 or 0.00% from the last close, which brings the market valuation of the company to $2.26B. OGN currently trades at a discount to its 52-week high of $23.10, offering almost -165.82% off that amount. The share price’s 52-week low was $8.01, which indicates that the current value has risen by an impressive 7.83% since then.
Organon & Co stock received a consensus recommendation rating of Hold, based on a mean score of 3.00. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 3 recommended OGN as a Hold, whereas 1 deemed it a Buy, and 2 rated it as Underweight. Organon & Co is expected to report earnings per share of 0.94 for the current quarter.
Organon & Co (NYSE:OGN) trade information
The performance over the last five days has remained in the red territory. The rise to weekly highs of 9.16 on recent trading dayincreased the stock’s daily price by 5.13%. The company’s shares are currently down -41.76% year-to-date, but still down -3.87% over the last five days. On the other hand, Organon & Co (NYSE:OGN) is -28.30% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $14, which translates to bulls needing to increase their stock price by 37.93% from its current value. Analyst projections state that OGN is forecast to be at a low of $10 and a high of $18.
Organon & Co (OGN) estimates and forecasts
The year-over-year growth rate is expected to be -2.81%, down from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 1.55B in revenue for the current quarter. 4 analysts expect Organon & Co to make 1.56B in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 1.61B and 1.58B respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -3.44%. Forecasts for the next quarter put sales growth at -1.66%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -23.49%. Organon & Co earnings are expected to increase by -6.05% in 2025, but the outlook is positive 1.19% per year for the next five years.
OGN Dividends
Organon & Co’s next quarterly earnings report is expected to be released in June. The annual dividend yield of the stock is 9.90 percent and its annual dividend per share was 0.86. It is important to note, however, that the 9.90% dividend yield ratio should be regarded as a guide only, as many other factors should be taken into consideration before making any investment decision.
VANGUARD GROUP INC, with 11.7429% or 30.21 million shares worth $625.41 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Trust-iShares Core S&P Small-Cap ETF and Pacer Funds Trust-Pacer US Cash Cows 100 ETF were the top two Mutual Funds as of Apr 30, 2025 . The former held 15.62 shares worth $135.75 million, making up 6.01% of all outstanding shares. On the other hand, Pacer Funds Trust-Pacer US Cash Cows 100 ETF held roughly 11.13 shares worth around $96.72 million, which represents about 4.28% of the total shares outstanding.
